Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15802 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Maria Buur Nordskov Gabe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk A/S, Søborg, Denmark. Hauptthemen laut MEDLINE: Gastric Emptying, Glucagon-Like Peptides, Energy Intake, Obesity. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
Aim
To investigate the effects of once‐daily oral semaglutide 50 mg on energy intake, appetite, control of eating and gastric emptying.
Methods
A clinical pharmacology, double‐blind study was conducted in 61 adults with obesity randomized to once‐daily oral semaglutide (dose‐escalated to 50 mg) or placebo for 20 weeks. Energy intake was measured during an ad libitum lunch, and participant‐reported appetite ratings and Control of Eating Questionnaire responses were assessed. Gastric emptying was measured using paracetamol absorption following a standardized breakfast.
Results
The relative change from baseline in ad libitum energy intake at week 20 (primary endpoint) was −39.2% points (95% confidence interval −59.0%, −19.4%) with semaglutide compared with placebo. Body weight was reduced by 9.8% with semaglutide and by 1.5% with placebo. Semaglutide reduced hunger, increased fullness and satiety, and was associated with fewer food cravings and better control of eating versus placebo. No statistically significant difference in gastric emptying was observed at week 20.
Conclusions
In participants with obesity, once‐daily oral semaglutide 50 mg reduced energy intake, body weight and appetite, and improved control of eating. There was no evidence of delayed gastric emptying at week 20, as measured through paracetamol absorption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk A/S, Søborg, Denmark.
- Parexel International GmbH, Berlin, Germany.
- Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
- Steno Diabetes Center Copenhagen, Herlev, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Maria Buur Nordskov Gabe, Filip Krag Knop, Morten Rix Hansen, Katrine Kirkeby, Charlotte Lindorff Adrian
Förderung
- Novo Nordisk A/S
Zitieren
APA
Gabe, M. B. N., Breitschaft, A., Knop, F. K., Hansen, M. R., Kirkeby, K., Rathor, N., & Adrian, C. L. (2024). Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15802
Vancouver
Gabe MBN, Breitschaft A, Knop FK, Hansen MR, Kirkeby K, Rathor N, et al. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15802
BibTeX
@article{Gabe2024,
author = {Gabe, Maria Buur Nordskov and Breitschaft, Astrid and Knop, Filip Krag and Hansen, Morten Rix and Kirkeby, Katrine and Rathor, Naveen and Adrian, Charlotte Lindorff},
title = {Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15802}
}
EUVIMED